XML 40 R28.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment and Geographic Information | 12 Months Ended
--- | ---
Sep. 30, 2022
Segment Reporting [Abstract] |
Segment and Geographic Information | 18. Segment and Geographic Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker. The Company operates in two reportable segments: the Life Sciences Products segment and the Life Sciences Services segment. These reportable segments also represent the Company’s operating segments. The Company previously operated in three reportable segments: the Semiconductor Solutions Group segment, the Life Sciences Products segment, and the Life Sciences Services segment. As discussed in Note 3, “Discontinued Operations”, our Semiconductor Solutions Group reportable segment has been classified as a discontinued operation. The sale of the semiconductor automation business, which comprised the Semiconductor Solutions Group segment, was completed on February 1, 2022. Historical information has been adjusted to reflect the new reportable segments. Within our Life Sciences Products segment, we have developed and continue to develop automated biological sample storage solutions for operating in low temperature environments. We have a complete line up of automated stores from ambient temperatures to -190°C. Our BioStore’s ™ unique design allows controlled temperature storage down to -80°C with the industry’s highest throughput of sample retrieval. Within our Life Sciences Services segment, our genomics services business advances research and development activities by gene sequencing, synthesis, editing and related services. We offer a comprehensive, global portfolio that we believe has both broad appeal in the life sciences industry and enables customers to select the best solution for their research challenges. This portfolio also offers unique solutions for key markets such as cell and gene therapy, antibody development, and biomarker discovery by addressing genomic complexity and throughput challenges. Our sample repository solutions business is a global leader in sample storage and management, and provides a full suite of reliable cold and ultra-cold chain solutions. ​ The Company considers adjusted operating income, which excludes charges related to amortization of completed technology, restructuring related charges and other special charges, such as impairment losses, as the primary performance metric when evaluating the business. ​ The following is the summary of the financial information for the Company’s reportable segments for the fiscal years ended September 30, 2022, 2021 and 2020 (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Year Ended September 30,
​ | ​ | ​ | 2022 | ​ | 2021 | ​ | 2020
Revenue: |  | ​ |  |  | ​ |  |  | ​ |
Life Sciences Products | ​ | $ | 199,230 | ​ | $ | 199,606 | ​ | $ | 129,759
Life Sciences Services | ​ |  | 356,268 | ​ |  | 314,097 | ​ |  | 258,778
Total revenue | ​ | $ | 555,498 | ​ | $ | 513,703 | ​ | $ | 388,537
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income: | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​
Life Sciences Products | ​ | $ | 11,033 | ​ | $ | 23,094 | ​ | $ | (3,041)
Life Sciences Services | ​ |  | 10,784 | ​ |  | 22,659 | ​ |  | 2,859
Reportable segment adjusted operating income | ​ | ​ | 21,817 | ​ | ​ | 45,753 | ​ | ​ | (182)
Amortization of completed technology | ​ | ​ | 7,325 | ​ | ​ | 8,073 | ​ | ​ | 8,099
Restructuring related charges | ​ | ​ | — | ​ | ​ | 13,364 | ​ | ​ | 301
Amortization of acquired intangible assets | ​ | ​ | 24,965 | ​ | ​ | 29,299 | ​ | ​ | 27,276
Restructuring charges | ​ | ​ | 712 | ​ | ​ | 385 | ​ | ​ | 674
Other unallocated corporate expenses | ​ | ​ | 13,550 | ​ | ​ | 25,721 | ​ | ​ | 68
Total operating income | ​ | ​ | (24,735) | ​ | ​ | (31,089) | ​ | ​ | (36,600)
Interest income | ​ | ​ | 20,286 | ​ | ​ | 632 | ​ | ​ | 849
Interest expense | ​ | ​ | (4,589) | ​ | ​ | (2,037) | ​ | ​ | (2,944)
Loss on extinguishment of debt | ​ | ​ | (632) | ​ | ​ | — | ​ | ​ | —
Other expenses | ​ | ​ | (266) | ​ | ​ | (16,475) | ​ | ​ | (1,597)
Loss before income taxes | ​ | $ | (9,936) | ​ | $ | (48,969) | ​ | $ | (40,292)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ |  | ​ | ​ |  | ​ |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Assets: | ​ | ​ | Life Sciences Products | ​ | Life Sciences Services | ​ | Total
September 30, 2022 | ​ | $ | 378,790 | ​ | $ | 849,603 | ​ | $ | 1,228,393
September 30, 2021 | ​ |  | 278,769 | ​ | ​ | 780,238 | ​ | ​ | 1,059,007
​ ​ The following is a reconciliation of the Company’s reportable segments’ segment assets to the amounts presented in the accompanying Consolidated Balance Sheets as of September 30, 2022 and 2021 (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | September 30,
​ | ​ | 2022 | ​ | 2021
Segment assets |  | $ | 1,228,393 |  | $ | 1,059,007
Cash and cash equivalents, restricted cash, and marketable securities | ​ |  | 2,305,081 | ​ |  | 244,012
Deferred tax assets | ​ |  | 1,169 | ​ |  | 10,043
Other assets | ​ | ​ | 181,479 | ​ | ​ | 11,237
Assets held for sale | ​ |  | — | ​ |  | 495,213
Total assets | ​ | $ | 3,716,122 | ​ | $ | 1,819,512
​ ​ Revenue from external customers is attributed to geographic areas based on locations in which customer orders are placed. Net revenue by geographic area for the fiscal years ended September 30, 2022, 2021 and 2020 are as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Year Ended September 30,
​ |  | ​ | 2022 |  | 2021 |  | 2020
Geographic Location: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
North America | ​ | ​ | $ | 373,611 | ​ | $ | 323,982 | ​ | $ | 256,174
Europe | ​ | ​ | ​ | 104,824 | ​ | ​ | 108,805 | ​ | ​ | 74,155
China | ​ | ​ | ​ | 48,094 | ​ | ​ | 45,743 | ​ | ​ | 34,016
Asia Pacific/ Other | ​ | ​ |  | 28,969 | ​ |  | 35,173 | ​ |  | 24,192
Total | ​ | ​ | $ | 555,498 | ​ | $ | 513,703 | ​ | $ | 388,537
​ ​ The majority of the Company’s net revenue in North America is generated in the United States which amounted to $370.6 million, $320.8 million and $253.5 million, respectively, during fiscal years ended September 30, 2022, 2021 and 2020. Property, plant and equipment by geographic area as of September 30, 2022 and 2021 are as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30,
​ |  | 2022 |  | 2021
North America | ​ | $ | 84,852 | ​ | $ | 55,943
China | ​ | ​ | 56,585 | ​ | ​ | 54,239
Europe | ​ | ​ | 11,610 | ​ | ​ | 16,882
Asia / Pacific/ Other | ​ |  | 1,423 | ​ |  | 3,655
​ | ​ | $ | 154,470 | ​ | $ | 130,719
​ ​ Property, plant and equipment located in the United States amounted to $84.8 million and $60.6 million, respectively, at September 30, 2022 and 2021.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration